|
|
 Previous Article | Table of Contents | Next Article 
Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin
in the drug resistance of ATL to adriamycin
J Wang, M Kobayashi, K Sakurada, M Imamura, T Moriuchi and M Hosokawa
The Third Department of Internal Medicine, Hokkaido University School of
Medicine, Kita-ku, Sapporo, Japan.
Chemotherapy for adult T-cell leukemia (ATL) has been reported to fail to
induce complete remission because of drug resistance in most patients. We
have examined the expression of an ATL-derived factor (ADF)/thioredoxin in
relation to resistance to adriamycin (ADM) in various T-cell leukemia cell
lines including ATL cell lines. Immunoblot analysis demonstrated that ATL
cell lines expressed ADF/thioredoxin at levels 2.8 to 12 times those of
other T-cell acute lymphocytic leukemia (T-ALL) cell lines, and that ATL
cell lines were 2 to 15 times more resistant to ADM than other T-ALL cell
lines. Therefore, we established ADM-resistant cell lines from three
different ATL cell lines, and examined the correlation between ADM
resistance and expression of ADF/thioredoxin. ADM-resistant ATL cell lines
were also found to be resistant to other drugs such as cisplatin and
etoposide, and they expressed ADF/thioredoxin at levels 5 to 10 times those
of parent ATL cell lines. Diamide and sodium selenite, which have been
reported to inhibit ADF/thioredoxin, restored the sensitivity to ADM in ATL
and ADM- resistant ATL cell lines. The MDR-1 gene product, a membrane P-
glycoprotein (Pgp), was not expressed on ATL cell lines or ADM- resistant
ATL cell lines. Topoisomerase II and glutathione peroxidase activities in
T-cell leukemia cell lines were not correlated with ADM resistance. These
results suggest that ADF/thioredoxin may play an important role in the drug
resistance of ATL cells to ADM.
Volume 89,
Issue 7,
pp. 2480-2487,
04/01/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Kobayashi-Miura, K. Shioji, Y. Hoshino, H. Masutani, H. Nakamura, and J. Yodoi
Oxygen sensing and redox signaling: the role of thioredoxin in embryonic development and cardiac diseases
Am J Physiol Heart Circ Physiol,
May 1, 2007;
292(5):
H2040 - H2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ravi, H. Muniyappa, and K. C. Das
Endogenous Thioredoxin Is Required for Redox Cycling of Anthracyclines and p53-dependent Apoptosis in Cancer Cells
J. Biol. Chem.,
December 2, 2005;
280(48):
40084 - 40096.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yegorova, A. Liu, and M. F. Lou
Human Lens Thioredoxin: Molecular Cloning and Functional Characterization
Invest. Ophthalmol. Vis. Sci.,
August 1, 2003;
44(8):
3263 - 3271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shioji, C. Kishimoto, H. Nakamura, H. Masutani, Z. Yuan, S.-i. Oka, and J. Yodoi
Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity
Circulation,
September 10, 2002;
106(11):
1403 - 1409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pallis, M. Grundy, J. Turzanski, R. Kofler, and N. Russell
Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status
Blood,
July 15, 2001;
98(2):
405 - 413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kudoh, M. Takano, T. Koshikawa, M. Hirai, S. Yoshida, Y. Mano, K. Yamamoto, K. Ishii, T. Kita, Y. Kikuchi, et al.
Gains of 1q21-q22 and 13q12-q14 Are Potential Indicators for Resistance to Cisplatin-based Chemotherapy in Ovarian Cancer Patients
Clin. Cancer Res.,
September 1, 1999;
5(9):
2526 - 2531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Zhang, B. Liu, S. W. Kang, M. S. Seo, S. G. Rhee, and L. M. Obeid
Thioredoxin Peroxidase Is a Novel Inhibitor of Apoptosis with a Mechanism Distinct from That of Bcl-2
J. Biol. Chem.,
December 5, 1997;
272(49):
30615 - 30618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
